Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) dropped 3.8% during trading on Wednesday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8 %
The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05. The company has a market cap of C$168.68 million and a PE ratio of -28.19. The company’s 50 day moving average is C$10.60 and its 200 day moving average is C$10.60.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
See Also
- Five stocks we like better than BriaCell Therapeutics
- How to Choose Top Rated Stocks
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- What is a buyback in stocks? A comprehensive guide for investors
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Manufacturing Stocks Investing
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.